Contract 36F79723D0238
Mylan Institutional Llc · Department Of Veterans Affairs · September 29, 2023
Mylan Institutional Llc was awarded a federal contract by Department Of Veterans Affairs on September 29, 2023 for an undisclosed amount of work in pharmaceutical preparation manufacturing. It was awarded under full and open competition. The contract has been modified 9 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on March 4, 2026. If all options are exercised, the contract could reach $94.00 million.
Contract details
- PIID
- 36F79723D0238
- Award type
- Fss
- Pricing
- Fixed Price With Economic Price Adjustment
- Set-aside
- No Set Aside Used.
- Competition
- Full And Open Competition
- NAICS
- 325412 · Pharmaceutical Preparation Manufacturing
- Product / service
- Drugs And Biologicals
- First action
- September 29, 2023
- Latest action
- March 4, 2026
Description
TO UPDATE EMAIL ADDRESS IN NAC-CM
Modification timeline
-
March 4, 2026Mod P00030 · Supplemental Agreement For Work Within Scope$0
-
February 6, 2026Mod P00029 · Add Subcontracting PlanAPPROVED 2026 SUB-K PLAN$0
-
December 15, 2025Mod P00027 · Supplemental Agreement For Work Within Scope42-2A - 2026 PUBLIC LAW 102-585 PRICING UPDATE (DUAL PRICING)$0
-
October 29, 2025Mod P00026 · Supplemental Agreement For Work Within Scope651B - SINS 42-2A & 42-2B - PERMANENT PRICE DECREASE - BIG 4, OGA & FSS$0
-
August 5, 2025Mod P00025 · Supplemental Agreement For Work Within Scope651B - SIN 42-2A - PERMANENT PRICE DECREASE - BIG 4 AND OGA$0
-
April 9, 2025Mod P00022$0
-
September 23, 2024Mod P00009 · Supplemental Agreement For Work Within Scope65IB - SIN 42-2A - TRACKING CUSTOMER (TC) CHANGE / PERMANENT PRICE REDUCTION$0
-
September 23, 2024Mod P00010 · Supplemental Agreement For Work Within Scope65IB - SIN 42-2A - TRACKING CUSTOMER (TC) CHANGE$0
-
September 16, 2024Mod P00008 · Supplemental Agreement For Work Within Scope65IB - SIN 42-2A - PRODUCT DELETION - DISCONTINUED MANUFACTURING$0
-
September 29, 2023Base award65 I B, DRUGS, PHARMACEUTICALS, & HEMATOLOGY RELATED PRODUCTS, FSS CONTRACT AWARD$0
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Petnet Solutions, Inc. | Department Of Veterans Affairs | April 1, 2026 | $387.4K |
| Eli Lilly And Company | Department Of Veterans Affairs | April 1, 2026 | $0 |
| Exelan Pharmaceuticals Inc | Department Of Veterans Affairs | April 1, 2026 | $0 |
| Cardinal Health 414, Llc | Department Of Veterans Affairs | April 1, 2026 | $122.9K |
| Guardian Pharmacy Of Indianapolis Nuclear, Llc | Department Of Veterans Affairs | April 1, 2026 | $0 |
| Jubilant Draximage Inc | Department Of Veterans Affairs | April 1, 2026 | $0 |
Top contractors in NAICS 325412
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Mckesson Corporation | 1,187 | $4.96B |
| 2 | Merck Sharp & Dohme Llc | 26 | $894.71M |
| 3 | Sanofi Vaccines Us Inc. | 57 | $702.38M |
| 4 | Pfizer Inc | 169 | $541.15M |
| 5 | Glaxosmithkline, Llc | 14 | $505.04M |
| 6 | Phlow Corp. | 1 | $105.27M |
| 7 | Exelan Pharmaceuticals Inc | 76 | $104.30M |
| 8 | Seqirus USA Inc | 47 | $59.15M |
| 9 | Emergent Biosolutions Canada Inc | 2 | $53.73M |
| 10 | Mckesson Specialty Distribution Llc | 1 | $51.05M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 36F79723D0238?
Contract 36F79723D0238 is a federal contract awarded to Mylan Institutional Llc by Department Of Veterans Affairs on September 29, 2023 for an undisclosed amount of work classified under PHARMACEUTICAL PREPARATION MANUFACTURING. It has been modified 9 times since the base award.
Who won contract 36F79723D0238?
Mylan Institutional Llc won contract 36F79723D0238 from Department Of Veterans Affairs.
How much is contract 36F79723D0238 worth?
Contract 36F79723D0238 has obligated $0 to date but carries a potential ceiling of $94.00 million if fully funded and all options are exercised.